{'fraction_non_alphanumeric': 0.04387811634349031, 'fraction_numerical': 0.04265927977839335, 'mean_word_length': 4.864522417153996, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 2, 'lorem ipsum': 0, 'www.': 1, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
MicroRNA-520d-3p suppresses melanoma cells proliferation by inhibiting the anti-silencing function 1B histone chaperone

ABSTRACT As the most common and aggressive malignant form of skin cancer, melanoma has a poor prognosis in its late stage. MicroRNA (miR)-520d-3p has been reported as a key modulator that regulates the development of different types of cancer, but its role in melanoma remains unclear. The purpose of this study was to investigate the role and mechanism of miR-520d-3p in melanoma. The expression of anti-silencing function 1B histone chaperone (ASF1B) and miR-520d-3p in melanoma tissues and cells was detected by reverse transcription-quantitative polymerase chain reaction. The interaction between ASF1B and miR-520d-3p was verified by luciferase activity detection. Cell counting kit-8, bromodeoxyuridine, fluorescein isothiocyanate, and cell adhesion assays were performed to detect cell viability, proliferation, apoptosis, and adhesion in melanoma cells. ASF1B expression was evidently increased, whereas miR-520d-3p level was downregulated in melanoma tissues and cells. Overexpression of ASF1B enhanced cell growth and adhesion and hampered cell apoptosis in melanoma cells. Furthermore, miR-520d-3p suppressed the tumorigenic effects of melanoma cells. Moreover, miR-520d-3p suppressed the expression of ASF1B to suppress melanoma tumorigenesis. In conclusion, we have found out that miR-520d-3p suppressed melanoma tumorigenesis by inhibiting ASF1B, which could be a promising target for melanoma therapy.


Introduction
Melanoma is the most common and aggressive malignancy of skin cancer, with high incidence, metastatic rate, and mortality worldwide [1,2]. Although early stage melanoma is partly curable by surgical resection, advanced melanoma has poor prognosis [3]. Therefore, accurate diagnosis in the early stage is essential for improving the prognosis of melanoma.
The anti-silencing function 1B histone chaperone (ASF1B) gene is located on chromosome 19q13.12 and consists of four exons. It encodes a member of the H3/H4 family of histone chaperone proteins, which may play a key role in modulating the nucleosome structure of chromatin by constantly supplying histones at sites of nucleosome assembly [4,5]. ASF1B has been reported to be implicated in various cellular functions related to cancer pathogenesis and progression, such as cervical cancer, prostate cancer, and clear cell renal cell carcinoma, which could enhance cell growth and migration, but reduce cell apoptosis [4,6,7]. However, the role of ASF1B in melanoma has not been clearly elucidated.
MicroRNAs (miRNAs), approximately 22 nucleotides in length, are an abundant class of small non-coding RNAs that serve as gene regulators by preventing mRNA translation or mRNA degradation [8]. Different miRNAs functioning as tumor suppressors or oncogenes contribute to human cancer cell growth and apoptosis [9,10]. The miR-520d-3p has been reported as a key modulator in different types of cancers by regulating cell growth, migration, invasion, and apoptosis, such as breast cancer, hepatocellular carcinoma, gastric cancer, and ovarian cancer [11][12][13][14]. Nevertheless, whether miR-520d-3p plays a role in the progression of melanoma remains unclear.
In this study, we have attempted to obtain a thorough understanding of the mechanism of the miR-520d-3p-ASF1B axis in melanoma. We studied the effect of the miR-520d-3p-ASF1B axis on the malignant behavior of melanoma cells in vitro and found that miR-520d-3p suppresses ASF1B to hamper the progression of melanoma based on the targeted regulatory mechanisms of miRNAs and mRNAs. Our study may deepen our understanding of the miR-520d-3p-ASF1B axis in melanoma development and highlights the potential of the miR-520d-3p-ASF1B axis as a new target for melanoma therapy.

Tissue samples, cell lines, and cell transfection
A total of 38 melanoma and normal tissues from patients with melanoma were collected from our hospital with informed consent and approved by our hospital's ethics committee. The inclusion criteria for our study included patients diagnosed with melanoma by pathology and without a history of melanoma. The exclusion criteria were organ dysfunction, other malignant tumors, other skin diseases, and infectious and autoimmune diseases.

RNA extraction and reverse transcription-quantitative polymerase chain reaction
The total mRNA of the tissues and cells was extracted using the Total RNA Extraction Kit (A27828, Thermo, USA). cDNA was transcribed using the Maxima First Strand cDNA Synthesis Kit (K1642, Thermo, USA). Subsequently, the Applied Biosystems PowerUp SYBR Green (Thermo, USA) was assessed by quantitative reverse transcription-polymerase chain reaction (RT-qPCR). The miRNA of the tissues and cells was extracted using the miRcute miRNA extraction kit (DP501, Tiangen, China). The cDNA was transcribed using the miRcute miRNA First Strand cDNA Synthesis Kit (KR211, Tiangen, China). Subsequently, RT-qPCR was performed using the miRcute Enhanced miRNA Fluorescence Quantitative Detection Kit (FP411, Tiangen, China). Relative ASF1B expression was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and miR-520d-3p expression was normalized to small RNA U6 (U6). The data were analyzed using the 2-ΔΔCt method [15]. All primer sequences are listed in Table 1.

Cell counting kit-8 assay
Cells of 5 × 10 3 density were cultured in 96-well plates. At four time points, that is, 0, 24, 48, and 72 h, and the medium was replaced with 90 µL fresh medium, and 10 µL CCK-8 working solution (Cat#: ab228554; Abcam, UK) was added to each well and incubated for another 2 h. The OD value was examined using a multimode plate reader (Thermo, USA) at each time point at a wavelength of 450 nm [7].

Bromodeoxyuridine assay
A375 and A875 cells of 2 × 10 4 density were cultured in 96-well plates with serum-free medium overnight. The next day, cells were maintained for 24 h in medium containing 10% FBS. Then, the BrdU Cell Proliferation Assay Kit (Cat#: 6813, CST, MA, USA) was used to detect cell proliferation. BrdU (10 μM) was added to the plate and incubated for 4 h and then incubated with secondary antibody for another 1 h. The OD value was examined using a multimode plate reader at a wavelength of 450 nm [17].

Apoptosis assay
As described in a study [18], fluorescein isothiocyanate (FITC) Annexin V Apoptosis Detection Kit was used to detect apoptosis in A375 and A875 cells (Cat#: 556547; BD, USA). Approximately 6 × 10 4 cells were harvested and suspended in 100 µL binding buffer; 5 µL FITC and 5 µL propidium iodide were added to the buffer and maintained in the dark for 15 min. After washing twice, cells were suspended in the binding buffer, detected by flow cytometry, and analyzed using FlowJo (Tree Star, USA).

Caspase 3 activity assay
A375 and A875 cells (2 × 10 4 ) were cultured in 96well plates. A caspase-3 activity assay kit (Cat#: 5723, CST, USA) was used to detect cell apoptosis. Cells were collected in the cell lysis buffer, and caspase-3 assay loading solution was added for 2 h at 37°C. Subsequently, the OD value was detected on a multimode-plate reader at a wavelength of 405 nm [19].

Cell adhesion assay
Cell adhesion assay was performed based on a previous study [20]. Collagen I solution (Cat#: C7661, Sigma, USA) was used to prepare the 96well cell adhesion plate. A375 and A875 cells (2 × 10 4 ) were cultured in 96-well plates. The next day, cells were washed and maintained in serum-free DMEM for 8 h. Subsequently, the cells were treated with 10 mM ethylenediaminetetraacetic acid (EDTA) for 10 min to dissociate the cells and suspended in DMEM (2 × 10 5 cells/ mL). Then, the cell suspension was added to the cell adhesion plate and incubated for 20 min at 37°C. After the cells adhered to the surface, nonadherent cells were washed away and incubated with DMEM containing 10% FBS for 4 h at 37°C. Subsequently, 10 μL of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide substrate (Cat#: C0009S, Beyotime, China) was added to the cells and incubated for 2 h. Then, 100 µL dimethyl sulfoxide was added to the cells, and the OD value was detected on a multimodeplate-reader (Thermo, USA) at a wavelength of 570 nm.

Luciferase assay
We purchased the pmiRGLO vectors with wildtype or mutated ASF1B 3 -untranslated regions (UTRs) from Tuoran Bio (Shanghai, China). A375 and A875 cells were cultured in a 24-well plate (2 × 10 5 cells); furthermore, we transfected the one of the vectors and either miR-NC or miR-520d-3p into the cells with Lipo2000. Cells were harvested and measured using the Luciferase Assay Kit (Cat#: RG027, Beyotime, China) after 72 h. Renilla activity was used as an internal control [21].

Statistical analysis
The experiment was performed thrice and the data are summarized as mean ± standard deviation. Independent sample t-tests were evaluated for two-group comparisons and one-way analysis of variance for multiple comparisons with GraphPad 6.0 (GraphPad, USA). The association between ASF1B and miR-520d-3p expression was evaluated using Pearson correlation analysis. Statistical significance was set at P < 0.05.

Results
In this study, we hypothesized that ASF1B is tumorigenic in melanoma and is targeted by miR-520d-3p. We analyzed ASF1B levels in melanoma tissues and cell lines. In addition, to investigate the role of ASF1B in melanoma, we examined the effects of ASF1B knockdown on the proliferation, apoptosis, and adhesion of melanoma cells. Moreover, we verified the targeted binding between ASF1B and miR-520d-3p, and further explored the role of ASF1B in the survival of melanoma cells mediated by miR-520d-3p.

The identification of downstream ASF1B of miR-520d-3p
miR-193b has been reported to be involved in melanoma progression [22][23][24]. To further explore the downstream of miR-193b involving the key mRNAs, GSE18512 from GEO DataSets (https:// www.ncbi.nlm.nih.gov/geo/) was selected because it stored the mRNA expression data in the melanoma cell samples with miR-193b inhibitor and melanoma cell samples with inhibitor negative control. By analyzing the GSE18512 data series, we identified 78 significantly downregulated genes after miR-193-3p upregulation. We selected the top 30 most downregulated genes ( Table 2) and uploaded them to the STRING database (https://string-db.org/). Protein-protein interaction network analysis showed that eight genes (CCNA2, CCNE2, ASF1B, KIAA0101, MCM10, DTL, BARD1, and BRIP1) were closely correlated with strong confidence (Figure 1(a)). Among the eight genes, we found that ASF1B was significantly upregulated in melanoma (Figure 1(b), data from GEPIA database, http://gepia2.cancer-pku.cn/). In addition, ASF1B has been suggested to be a significant promoter of tumor in other cancers [4,6,7] but has not been studied in melanoma. In addition, miR-193b could be identified as an miRNA that targets ASF1B by GSE18512. Therefore, to further identify the candidate miRNAs regulating ASF1B, we intersected the miRNAs predicted by TargetScan algorithm (version: 7.2) and the differentially expressed miRNAs in melanoma from GSE61741 with the criteria of adjusted P < 0.05, and logFC ≤ −1.5. Five common miRNAs were identified: hsa-miR-300, hsa-miR -520d-3p, hsa-miR-767-3p, hsa-miR-1827, and hsa-miR-548d-3p (Figure 1(c)). Among the five miRNAs, miR-520d-3p attracted our attention because of its anticancer effect in multiple cancers [11,13,14] and for the reason that no study has been performed to find out its effect in melanoma [25].

The expression of ASF1B was elevated in melanoma
To assess the effect of ASF1B in melanoma, we first detected the expression of ASF1B in 38 pairs of tumor and normal tissues from patients with melanoma. ASF1B expression in the melanoma tissues was obviously 4-fold higher than that in normal tissues (1.00 ± 0.44 in normal tissues, 4.32 ± 1.59 in tumor tissues) (Figure 2(a)). Meanwhile, the expression of ASF1B in melanoma cells (A875, A375, WM35, and A2058) was dramatically higher than that in normal HaCAT cells; in particular, A375 and A875 cells showed the highest levels of these cell lines (1.00 ± 0.05 in HaCAT, 4.64 ± 0.18 in A375, 5.36 ± 0.49 in A875, 3.28 ± 0.37 in WM35, and 4.32 ± 1.59 in A2058 cells) (Figure 2(b)). Similarly, the melanoma cells also had significantly increased ASF1B protein levels compared to normal HaCAT cells (1.00 ± 0.08 in HaCAT, 2.68 ± 0.26 in A375, 2.92 ± 0.32 in A875, 1.92 ± 0.13 in WM35, and 0.89 ± 0.06 in A2058) (Figure 2(c)). Thus, we selected the A375 and A875 cell lines for further analysis. We transfected Si-NC, Si-ASF1B, and OE-ASF1B into the A375 and A875 cells. The OE-ASF1B cells exhibited by 5-fold upregulated ASF1B

Discussion
Although early stage melanoma is partly curable by surgical resection, advanced melanoma has poor prognosis [26]. Recognizing the importance of melanoma, researchers have focused on improving the effectiveness of melanoma treatment through early and accurate screening and diagnosis [27]. In this study, we have revealed the mechanism of the miR-520d-3p-ASF1B axis in melanoma, providing a valuable theoretical basis for early screening and diagnosis of melanoma. In this study, we have shown that ASF1B expression was increased, while miR-520d-3p expression was reduced in melanoma tissues and cells. Upregulation of ASF1B enhanced cellular proliferation and adhesion, but triggered a decline in cellular apoptosis. Furthermore, miR-520d-3p upregulation reduced proliferation and adhesion, but elevated apoptosis in melanoma cells. Moreover, miR-520d-3p inhibited ASF1B to suppress melanogenesis.
repressing the PI3K/Akt pathway [6]. Liu et al. suggested that the overexpression of ASF1B facilitated cervical cancer development by stabilizing CDK9 [7]. In the current study, we elucidated the role of ASF1B in melanoma progression. We found an obvious increase in ASF1B expression in melanoma tissues and cells and induced ASF1B knockdown and overexpression in melanoma cells. The results suggested that ASF1B effectively elevated cellular proliferation and adhesion and hampered cellular apoptosis in melanoma cells.
Numerous attempts have been made to uncover the role of miRNAs in melanoma development by regulating cell growth and apoptosis. Evidence has shown that miR-942-5p accelerates human melanoma cell growth by reducing DKK3 expression [29]. Qiu et al. clarified that miRNA-138 downregulates hypoxia-inducible factor 1α and hampers melanoma cell growth and metastasis [30]. Furthermore, knockdown of miR-126-3p contributed to dabrafenib-acquired resistance in melanoma by elevating ADAM9 and VEGF-A [31]. Several studies have demonstrated the pivotal role of miR-520d-3p in cancer initiation and development, such as in breast cancer, hepatocellular carcinoma, and gastric cancer [11,13,14]. For instance, knockdown of miR-520d-3p promoted cell growth by inhibiting long non-coding RNA MIAT and EPHA2 expression in hepatocellular carcinoma [14]. In addition, Ren et al. found that miR-520d-3p prevented post-transcriptional regulation of spindle and kinetochore-associated 2 expression in breast cancer [13]. Furthermore, miRNA 520d-3p inhibits cell growth by reducing EphA2 expression in gastric cancer [11]. In agreement with their data, we have demonstrated that miR-520d-3p level was conspicuously elevated in melanoma tissues and cells. Inhibition of miR-520d-3p boosted cell growth and repressed apoptosis in melanoma cells. Moreover, miR-520d-3p suppressed the progression of melanoma cells by inhibiting ASF1B expression.
In our study, we have clarified that miR-520d-3p hampered the development of melanoma by inhibiting ASF1B expression, which could be a promising target for the clinical treatment of melanoma. Additionally, we will study the correlation between the miR-520d-3p-ASF1B axis and the prognosis of patients with melanoma and cancer histopathology once the opportunity arises. Furthermore, although we have confirmed the interaction between miR-520d-3p and ASF1B in melanoma cells in our study, the signaling pathways involved need to be elucidated. Moreover, the biological role of miR-520d-3p-ASF1B axis in melanoma needs to be verified and determined using animal models.

Conclusions
In conclusion, through our study, we clarified for the first time that miR-520d-3p hampered the development of melanoma by inhibiting ASF1B expression, which could be a promising target for the clinical treatment of melanoma. Additionally, future studies on melanoma screening and diagnosis may be carried out based on the regulatory mechanism of the miR-520d-3p-ASF1B axis. 1. ASF1B was upregulated in melanoma cells and facilitated proliferation and adhesion, but repressed cell apoptosis of melanoma cells. 2. miR-520d-3p targeted ASF1B. 3. miR-520d-3p was downregulated in melanoma cells and restrained proliferation and adhesion, but repressed cell apoptosis of melanoma cells. 4. miR-520d-3p hampered melanoma cell progression by inhibiting ASF1B.

Disclosure statement
No potential conflict of interest was reported by the author(s).

Funding
Funding information is not available.

Authors' contributions
NS conducted the study, collected, and analyzed the data. XS and XDX designed the study and methods. YJC interpreted the data, collected materials and resources. MNF conducted literature analysis and prepared manuscript. All authors read and approved the final manuscript.

Data sharing statement
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Consent to participate
All patients signed written informed consent.

Consent for publication
Consent for publication was obtained from the participants.

Ethical conduct of research statement
The present study was approved by the Ethics Committee of Huangshi Central Hospital (Huangshi, China). The processing of clinical tissue samples is in strict compliance with the ethical standards of the Declaration of Helsinki.